A randomized trial showed Optune monotherapy demonstrated efficacy comparable to that of chemotherapy*
Median OS was similar at 6.6 months with Optune monotherapy and 6.0 months with physician's choice of chemotherapy1,*
Overall Survival1

Twice as many patients responded to Optune vs physician’s choice of chemotherapy2


*Therapy options were the physician's best choice for chemotherapy. The best available therapy was prescribed according to local practice and depending on prior treatment exposure.1
OS correlated with treatment usage in a subgroup analysis of patients treated with Optune3,†
Subgroup analysis of patients receiving Optune

- OS was significantly higher in patients who received Optune for ≥18 hours per day (n=92) vs those who received therapy for <18 hours per day (n=28), 7.7 months vs 4.5 months, respectively3
- Median usage was 86% (range 41%-98%) of the time in each treatment month, translating into a mean use of 20.6 hours per day1
†From a post hoc analysis.
GBM, glioblastoma; OS, overall survival.
- Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48(14):2192-2202.
- Wong ET, Lok E, Swanson KD, et al. Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma. Cancer Med. 2014;3(3):592-602.
- Kanner AA, Wong ET, Villano JL, Ram Z; EF-11 Investigators. Corrigendum to "Post hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100ATM system versus best physician's choice of chemotherapy" [Seminars in Oncology, Vol 41, No 5, Suppl 6, October 2014, ppS25-S34]. Semin Oncol. 2015;42(3):e56-e66.